Article Figures & Data
Figures
- Figure 1.
Effect of oral administration of CI-1033 on tumor mass in mice bearing established A431, H125, MDA-MB-468, or SF767 xenografts. Efficacy studies: (A) A431 xenograft-bearing mice treated with vehicle or efficacious doses of CI-1033, (B) A431 xenograft-bearing mice treated with vehicle or subefficacious doses of CI-1033, (C) H125 xenograft-bearing mice treated with vehicle or efficacious doses of CI-1033, (D) H125 xenograft-bearing mice treated with vehicle or subefficacious doses of CI-1033, (E) SF767 xenograft-bearing mice treated with vehicle or CI-1033, and (F) MDA-MB-468 xenograft-bearing mice treated with vehicle or CI-1033. Tumor fragments were implanted s.c. as described in Materials and Methods on day 0. Xenografts were allowed to grow to ∼200 mg at which point therapy was initiated. CI-1033 was administered orally, daily for the duration of the experiment. Xenografts were measured with calipers and tumor mass was estimated twice weekly. A minimum of six mice were included in the evaluation of median tumor mass at each time point. *, statistical significance as determined by two-tailed t test comparison of CI-1033 and vehicle-treated control groups.
- Figure 2.
Effect of oral administration of CI-1033 on plasma VEGF levels in mice bearing established A431, H125, or SF767 xenografts. Plasma VEGF levels in (A) A431 xenograft-bearing mice treated with vehicle or efficacious doses of CI-1033, (B) A431 xenograft-bearing mice treated with vehicle or subefficacious doses of CI-1033, (C) H125 xenograft-bearing mice treated with vehicle or efficacious doses of CI-1033, (D) H125 xenograft-bearing mice treated with vehicle or subefficacious doses of CI-1033, and (E) SF767 xenograft-bearing mice treated with vehicle or CI-1033. At each time point, mice were sacrificed and plasma was isolated using an EDTA-primed syringe. Mouse plasma was analyzed for VEGF concentration by ELISA. *, significant difference from control.
- Figure 3.
Correlation of plasma VEGF levels with A431 and H125 tumor mass. Plasma VEGF levels in relation to tumor mass in (A) vehicle-treated A431 xenograft-bearing mice or (B) vehicle-treated H125 xenograft-bearing mice. At each time point, vehicle-treated mice were sacrificed and plasma was isolated using an EDTA-primed syringe. Mouse plasma was analyzed for VEGF concentration by ELISA.
- Figure 4.
Effect of oral administration of CI-1033 on VEGF mRNA levels in xenografts. Xenograft VEGF (4.4/5.4 kb transcript) or β-actin (loading control) expression in (A) A431 xenograft-bearing mice treated with vehicle or CI-1033 (12 or 40 mg/kg) at treatment days 1, 2, 3, 5, and 12 or (B) H125 xenograft-bearing mice treated with vehicle or CI-1033 1033 (20 or 40 mg/kg) at treatment days 2, 5, and 12. Expression of VEGF and β-actin were determined by Northern blotting.
- Figure 5.
Effect of oral administration of CI-1033 on plasma IL-8 levels in mice bearing established SF767, MDA-MB-468, or H125 xenografts. Plasma VEGF levels in (A) SF767 xenograft-bearing mice treated with vehicle or CI-1033, (B) MDA-MB-468 xenograft-bearing mice treated with vehicle or CI-1033, or (C) H125 xenograft-bearing mice treated with vehicle or CI-1033. At each time point, mice were sacrificed and plasma was isolated using an EDTA-primed syringe. Mouse plasma was analyzed for IL-8 concentration by ELISA. *, significant difference from control.
- Figure 6.
Correlation of plasma IL-8 levels with SF767 and MDA-MB-468 tumor mass. Plasma IL-8 levels in relation to tumor mass in (A) vehicle-treated SF767 xenograft-bearing mice or (B) vehicle-treated MDA-MB-468 xenograft-bearing mice. At each time point, vehicle-treated mice were sacrificed and plasma was isolated using an EDTA-primed syringe. Mouse plasma was analyzed for IL-8 concentration by ELISA.
- Figure 7.
Effect of oral administration of CI-1033 of IL-8 mRNA levels in xenografts. Xenograft IL-8 (1.8-kb transcript) or β-actin (loading control) expression in (A) SF767 xenograft-bearing mice treated with vehicle or CI-1033 (15 or 30 mg/kg) at treatment days 6, 12, and 18 or (B) MDA-MB-468 xenograft-bearing mice treated with vehicle or CI-1033 (5 or 30 mg/kg) at treatment days 7, 14, and 21. Expression of IL-8 and β-actin were determined by Northern blotting.
Volume 4, Issue 6
